TCF3 and acute lymphoblastic leukemia: Affected patients exhibit a characteristic B-cell immunophenotype (CD19+/CD10+/CD33−/CD34−/sIg−, and mostly cyIg+), and gene expression analyses have indicated that TCF3::PBX1-positive patients constitute a separate entity among ALL patients2–4.